reports
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 202...
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025 Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13%Operating cash flow of $579 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2025. Third Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 8% to $1.3 billion; up 9% on a constant currency basis Gross margin ...
Resmed Names Salli Schwartz as Chief Investor Relations Officer
Resmed Names Salli Schwartz as Chief Investor Relations Officer Former Illumina, MSCI, and Moody’s executive brings extensive experience leading engagement with the global investment community SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairm...
ResMed Inc: 1 director
A director at ResMed Inc sold 2,000 shares at 219.740USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, ...
Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US FDA-cleared home sleep test provides an effective and simplified solution to obstructive sleep apnea testing and diagnosis SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, ™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplified,...
Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025
Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025 SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2025 on Wednesday, April 23, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location: •Date:Wednesday, April 23, 2025 •Time:1:30 p.m. PD...
New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer
New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer Largest ever meta-analysis on the long-term benefits of CPAP therapy, published in The Lancet Respiratory Medicine, found that in people with sleep apnea, CPAP therapy lowered the overall chance of dying by 37% and the chance of heart-related death by 55%. SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark meta-analysis in , demonstrating that CPAP t...
Resmed Unveils Unified Brand to Lead the Global Sleep and Health Techn...
Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution Brand Evolution Unites Brands Under One Resmed Identity to Make Better Sleep and Breathing Health More Accessible to Everyone SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a comprehensive brand evolution designed to unify its brand portfolio to serve more people and healthcare providers worldwide and reflect growing direct to consumer engagement. For 35 year...
ResMed’s Fifth Annual Global Sleep Survey Reveals a World Struggling w...
ResMed’s Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships 7 out of 10 employed respondents have called in sick at least once in their career due to poor sleep.18% of couples reported sleeping in separate rooms due to snoring and restlessness.Women report fewer quality sleep nights and more difficulties falling asleep than men. SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- (NYSE: RMD, ASX: RMD), a global health technology lead...
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 20...
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025 Year-over-year revenue grows 10%, operating profit up 52%, non-GAAP operating profit up 19%Operating cash flow of $309 million Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2024. Second Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 10% to $1.3 billion; up 10% on a constant currency basis Gross ...
ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 20...
ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025 SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2025 on Thursday, January 30, 2025, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: • Location:• Date:Thursday, January 30, 2025• Time:1:30 p....
ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthca...
ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, beginning at approximately 3:00 p.m. (Pacific Standard Time) in San Francisco, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting . The audio-only webcast replay ...
ResMed Announces Participation in the UBS Global Healthcare Conference
ResMed Announces Participation in the UBS Global Healthcare Conference SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 3:30 p.m. (Pacific Standard Time) at the Terranea Resort Hotel in Rancho Palos Verdes, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visit...
ResMed to Report First Quarter Fiscal 2025 Earnings on October 24, 202...
ResMed to Report First Quarter Fiscal 2025 Earnings on October 24, 2024 SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2025 on Thursday, October 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location: Date: Thursday, October 24, 2024 Ti...
ResMed Unveils 2030 Strategy to Drive Growth, Profitability, and Share...
ResMed Unveils 2030 Strategy to Drive Growth, Profitability, and Shareholder Returns 2030 ambition to help more than 500 million people worldwide achieve their full health potentialShowcases integration of intelligent products and solutions within the ResMed ecosystem, designed to deliver a better experience, lower costs, and enhanced outcomes for patients and providersIntroduces updated five-year financial outlook NEW YORK and SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today unveiled its 2030 Strategy to drive growth, profitability, and shareholder ...
UPDATE -- ResMed Unveils New Collection of Digital and Personalized So...
UPDATE -- ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health ResMed makes it easier for people to manage their sleep health and stay on (continuous positive airway pressure) CPAP treatment by integrating its leading myAir™ consumer app with Apple and Android smartwatches. Introduces a Generative AI-enabled sleep health assistant to guide people on their journey to better sleep and new travel gear to help people stay on CPAP treatment while traveling. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- (NYSE: RMD, ASX: RMD), the world’s leadin...
UPDATE -- ResMed Enhances CPAP Therapy with its First Fabric Mask, Des...
UPDATE -- ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier for People to Embrace Their Treatment and Improve Overall Sleep Health The new AirTouch™ N30i tube-up nasal mask for CPAP combines softness, breathability, and a high-performance, durable seal to provide exceptional comfort SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a ResMed first in CPAP (continuous positive airway pressure) mask innovation with ...
ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to M...
ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier for People to Embrace Their Treatment and Improve Overall Sleep Health The new AirTouch™ N30i tube-up nasal mask for CPAP combines softness, breathability, and a high-performance, durable seal to provide exceptional comfort SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a ResMed first in CPAP (continuous positive airway pressure) mask innovation with the launch...
ResMed Unveils New Collection of Digital and Personalized Solutions de...
ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health ResMed makes it easier for people to manage their sleep health and stay on (continuous positive airway pressure) CPAP treatment by integrating its leading myAir™ consumer app with Apple and Android smartwatches. Introduces a Generative AI-enabled sleep health assistant to guide people on their journey to better sleep and new travel gear to help people stay on CPAP treatment while traveling. SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- (NYSE: RMD, ASX: RMD), the world’s leading health t...
ResMed to Host Its 2024 Investor Day on September 30, 2024, at the New...
ResMed to Host Its 2024 Investor Day on September 30, 2024, at the New York Stock Exchange Learn more about ResMed’s 2030 strategy to accelerate growthJoin in person or via virtual webcast SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) will host an investor day on Monday, September 30, 2024, beginning at approximately 1:00 p.m. (Eastern Daylight Time). As previously announced, the event will be held at the New York Stock Exchange in New York City and simultaneously webcast online. More information about this event, including access to the live webcast...
Vaping Expected to Increase COPD Health and Economic Burden by 2050
Vaping Expected to Increase COPD Health and Economic Burden by 2050 New ResMed-supported research presented at ERS 2024 projects future Chronic Obstructive Pulmonary Disease (COPD) burden in Western Europe, accounting for increased air pollution, tobacco smoking, and vaping, with Non-Invasive Ventilation (NIV) enhancing survival rates. 88.7 million new COPD hospitalizations projected across Western Europe between 2019 - 2050Vaping projected to incur almost €30 billion additional direct and indirect costs by 2050€4.9 trillion projected cumulative cost to support COPD lung conditions by 2050...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.